Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy. — Stella

Recruiting

Back to Atrial Fibrillation trials

Trial locations(1 site)

United States

Tulane University School of Medicine, New Orleans, Louisiana

Key details

Sponsor

Tulane University School of Medicine

Collaborators

Samsung, Preventice

Enrollment target

~360 participants

Started

April 2025

Primary completion

December 2027

Age range

18 Years – 79 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov